News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Drugs RG1678 Show Promise Treating Schizophrenia, Blood Cancer in Mid-Stage Studies
December 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH Dec 6 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) presented the results of studies on two drugs in mid-stage development that may go some way towards addressing concerns about the strength of the company's drug pipeline.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
Roche
MORE ON THIS TOPIC
Obesity
Novo Bounces Back With ‘Competitive’ Mid-Stage Weight Loss Data for Amycretin
November 25, 2025
·
2 min read
·
Tristan Manalac
Cancer
ASH25: Late-Stage Data For J&J’s Tecvayli/Darzalex Combo Could ‘Shift Paradigm’ in Myeloma
November 25, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
J&J’s Anti-Tau Bet Falls Flat in Mid-Stage Alzheimer’s Trial
November 24, 2025
·
1 min read
·
Heather McKenzie
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
November 24, 2025
·
3 min read
·
Heather McKenzie
